Page last updated: 2024-10-23

seratrodast and Asthma

seratrodast has been researched along with Asthma in 31 studies

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
" Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic."9.10The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. ( Fukuoka, T; Inase, N; Miyake, S; Tojo, N; Umino, T; Yoshizawa, Y, 2003)
"Seratrodast, a potent thromboxane receptor antagonist, is approved in Japan for the treatment of asthma and currently is being developed in the United States."9.08Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. ( Cao, G; Dean, R; Granneman, GR; Killian, A; Locke, C; Samara, E, 1997)
"Coupling seratrodast (SD), an antiasthmatic drug, with several different types of NO donors including oxatriazoles, N-hydroxyguanidines and furoxans; evaluating the antiasthmatic effects of coupled compounds by determining their inhibitory activity of guinea pig asthma induced by acetylcholine and histamine; and assessing NO releasing ability."7.72[Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives]. ( Feng, XC; Ji, H; Qiu, SG; Zhang, YH; Zhang, ZG, 2004)
"Seratrodast, an antagonist to thromboxane A2 (TXA2) receptors, is not always effective in patients with bronchial asthma."7.71[Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. ( Kotajima, R; Muramatsu, H; Sato, T, 2001)
"We examined effects of a thromboxane A2 (TXA2) antagonist seratrodast on airway hyperresponsiveness, exhaled nitric oxide (NO), and eosinophils in induced sputum in 14 asthmatics."7.70Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics. ( Aizawa, H; Fukuyama, S; Hara, N; Inoue, H; Koto, H; Matsumoto, K; Nakano, H; Yoshida, M, 1998)
"Bronchial asthma is a disease defined by reversible airway obstruction, bronchial hyperresponsiveness and inflammation."6.41Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. ( Benoit, P; de Leval, X; Delarge, J; Dogné, JM; Masereel, B, 2002)
" Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic."5.10The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. ( Fukuoka, T; Inase, N; Miyake, S; Tojo, N; Umino, T; Yoshizawa, Y, 2003)
"beta-adrenoreceptor blockers such as propranolol provoke bronchoconstriction only in asthmatic patients."5.09Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. ( Abo, M; Fujimura, M; Hashimoto, T; Ishiura, Y; Kamio, Y; Matsuda, T; Myou, S, 1999)
"To determine the effects of a specific thromboxane A(2) (TxA(2)) receptor antagonist, seratrodast, on asthma control and airway secretions."5.09Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. ( Isono, K; Kondo, M; Nagai, A; Nagano, Y; Nakata, J; Tamaoki, J, 2000)
"Seratrodast, a potent thromboxane receptor antagonist, is approved in Japan for the treatment of asthma and currently is being developed in the United States."5.08Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. ( Cao, G; Dean, R; Granneman, GR; Killian, A; Locke, C; Samara, E, 1997)
"Thromboxane A2 (TxA2) plays an important role in asthma."4.81[Thromboxane A2 synthase inhibitor and receptor antagonist]. ( Adachi, M; Minoguchi, K, 2001)
"Coupling seratrodast (SD), an antiasthmatic drug, with several different types of NO donors including oxatriazoles, N-hydroxyguanidines and furoxans; evaluating the antiasthmatic effects of coupled compounds by determining their inhibitory activity of guinea pig asthma induced by acetylcholine and histamine; and assessing NO releasing ability."3.72[Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives]. ( Feng, XC; Ji, H; Qiu, SG; Zhang, YH; Zhang, ZG, 2004)
"Seratrodast, an antagonist to thromboxane A2 (TXA2) receptors, is not always effective in patients with bronchial asthma."3.71[Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. ( Kotajima, R; Muramatsu, H; Sato, T, 2001)
"We examined effects of a thromboxane A2 (TXA2) antagonist seratrodast on airway hyperresponsiveness, exhaled nitric oxide (NO), and eosinophils in induced sputum in 14 asthmatics."3.70Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics. ( Aizawa, H; Fukuyama, S; Hara, N; Inoue, H; Koto, H; Matsumoto, K; Nakano, H; Yoshida, M, 1998)
"The contributions of histamine, cysteinyl leukotrienes (CysLTs) and thromboxane A2 (TXA2) to the asthmatic responses and the magnitudes of blood and lung eosinophilia at acute and chronic stages of our asthmatic model were comparatively determined."3.70Repeated antigen inhalations alter chemical mediators that cause asthmatic obstruction in guinea pigs. ( Kohno, S; Nabe, T; Tomioka, H; Yamashita, K, 1999)
"The effects of lipid mediator antagonists: the LTD4-receptor antagonist pranlukast, the TXA2-receptor antagonist seratrodast, and the novel dual LTD4- and TXA2-receptor antagonist YM158 (3-[(4-tert-butylthiazol-2-yl)methoxy]-5'-[3-(4-chlorobenzenesu lfonyl) propyl]-2'-(1H-tetrazol-5-ylmethoxy)benzanilide monosodium salt monohydrate) were investigated in animals exhibiting immediate asthmatic response (IAR), late asthmatic response (LAR) and airway hyper-responsiveness (AHR)."3.70Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs. ( Arakida, Y; Honda, K; Miyata, K; Morio, H; Ohga, K; Okada, Y; Suwa, K; Yamada, T; Yokota, M, 2000)
"Seratrodast did not suppress IAR or LAR."2.69Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. ( Asai, S; Kohno, S; Matsuo, N; Matsuse, H; Obase, Y; Shimoda, T, 1998)
"COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma are two severe lung diseases which represent a major problem of world public health."2.43Prostanoids as pharmacological targets in COPD and asthma. ( Dogné, JM; Masereel, B; Rolin, S, 2006)
"Bronchial asthma is a disease defined by reversible airway obstruction, bronchial hyperresponsiveness and inflammation."2.41Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. ( Benoit, P; de Leval, X; Delarge, J; Dogné, JM; Masereel, B, 2002)

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19902 (6.45)18.7374
1990's17 (54.84)18.2507
2000's11 (35.48)29.6817
2010's0 (0.00)24.3611
2020's1 (3.23)2.80

Authors

AuthorsStudies
Shiraishi, M2
Kato, K2
Terao, S2
Ashida, Y5
Terashita, Z1
Kito, G1
Powell, WS1
Baba, K1
Sakakibara, A1
Yagi, T1
Niwa, S1
Wakayama, H1
Takagi, K1
Fukuoka, T1
Miyake, S1
Umino, T1
Inase, N1
Tojo, N1
Yoshizawa, Y1
Dogné, JM2
de Leval, X1
Benoit, P1
Delarge, J1
Masereel, B2
Zhang, ZG1
Zhang, YH1
Ji, H1
Qiu, SG1
Feng, XC1
Rolin, S1
Obayashi, O1
Ohta, K1
Matsumoto, T4
Tsukuda, R1
Kurokawa, T1
Sasada, R1
Iwasa, S1
Hada, S2
Hashizume, M2
Nishii, S2
Yoshioka, F2
Yasunaga, K2
Endo, S1
Akiyama, K1
Kagoshima, M2
Tomomatsu, N2
Iwahisa, Y2
Yamaguchi, S2
Kawakami, Y2
Terasawa, M2
Matsuura, M1
Samara, E1
Cao, G1
Locke, C1
Granneman, GR1
Dean, R1
Killian, A1
Obase, Y2
Shimoda, T2
Matsuo, N2
Matsuse, H2
Asai, S2
Kohno, S3
Aizawa, H1
Inoue, H1
Nakano, H1
Matsumoto, K1
Yoshida, M1
Fukuyama, S1
Koto, H1
Hara, N1
Fukushima, C1
Takao, A1
Ayabe, H1
Hoshino, M1
Sim, J1
Shimizu, K1
Nakayama, H1
Koya, A1
Yamashita, K1
Nabe, T1
Tomioka, H1
Fujimura, M2
Abo, M1
Kamio, Y1
Myou, S1
Ishiura, Y1
Hashimoto, T1
Matsuda, T2
Tanaka, H1
Igarashi, T1
Saitoh, T1
Teramoto, S1
Miyazaki, N1
Kaneko, S1
Ohmichi, M1
Abe, S1
Arakida, Y2
Ohga, K2
Suwa, K2
Okada, Y2
Morio, H2
Yokota, M2
Miyata, K1
Yamada, T2
Honda, K1
Tamaoki, J1
Kondo, M1
Nakata, J1
Nagano, Y1
Isono, K1
Nagai, A1
Muramatsu, H1
Kotajima, R1
Sato, T1
Minoguchi, K1
Adachi, M1
Sakamoto, S1
Saito, M1
Miyake, Y1
Kuriki, H2
Saijo, T1
Kurokawa, D1

Reviews

6 reviews available for seratrodast and Asthma

ArticleYear
Eicosanoid receptors as therapeutic targets for asthma.
    Clinical science (London, England : 1979), 2021, 08-27, Volume: 135, Issue:16

    Topics: Acetates; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Benzoquinones; Biomarker

2021
Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.
    American journal of respiratory medicine : drugs, devices, and other interventions, 2002, Volume: 1, Issue:1

    Topics: Anti-Asthmatic Agents; Asthma; Benzoquinones; Carbazoles; Heptanoic Acids; Humans; Methacrylates; Mo

2002
Prostanoids as pharmacological targets in COPD and asthma.
    European journal of pharmacology, 2006, Mar-08, Volume: 533, Issue:1-3

    Topics: Animals; Asthma; Benzoquinones; Carbazoles; Enzyme Inhibitors; F2-Isoprostanes; Heptanoic Acids; Hum

2006
[Adverse effects of thromboxane receptor antagonists and synthase inhibitors].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Oct-28, Volume: 65 Suppl 8

    Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Asthma; Benzoquinones; Chemical and Drug Induc

2007
[Thromboxane A2 receptor antagonist in asthma therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:11

    Topics: Asthma; Benzoquinones; Bridged Bicyclo Compounds; Bronchi; Bronchial Hyperreactivity; Carbazoles; Fa

1996
[Thromboxane A2 synthase inhibitor and receptor antagonist].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10

    Topics: Asthma; Benzoquinones; Bronchi; Bronchial Hyperreactivity; Eosinophils; Heptanoic Acids; Humans; Met

2001

Trials

9 trials available for seratrodast and Asthma

ArticleYear
Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.
    Respirology (Carlton, Vic.), 2002, Volume: 7, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Asthma; Beclomethasone; Benzoquinones; Blood Proteins; Chromones;

2002
The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:3

    Topics: Adult; Anti-Asthmatic Agents; Asthma; Benzoquinones; Blood Proteins; Bronchial Hyperreactivity; Cros

2003
Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma.
    Clinical pharmacology and therapeutics, 1997, Volume: 62, Issue:4

    Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Double-Blind Method; Female; Forced Expir

1997
Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
    Chest, 1998, Volume: 114, Issue:4

    Topics: Administration, Oral; Adult; Anti-Asthmatic Agents; Antigens; Asthma; Benzoquinones; Blood Proteins;

1998
Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:6

    Topics: Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Benzoquinones; Biopsy; Bronchi; Bronchial Hyperrea

1999
Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:6

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Asthma; Benzoquinones; Bronchoconstriction; Chromones; Dou

1999
Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients?
    Respiratory medicine, 1999, Volume: 93, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Creatinine;

1999
Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma.
    Chest, 2000, Volume: 118, Issue:1

    Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Double-Blind Method; Heptanoic Acids; Hum

2000
Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma.
    The Journal of allergy and clinical immunology, 1991, Volume: 87, Issue:1 Pt 1

    Topics: Adult; Aged; Asthma; Benzoquinones; Bronchi; Dose-Response Relationship, Drug; Drug Synergism; Femal

1991

Other Studies

16 other studies available for seratrodast and Asthma

ArticleYear
Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation.
    Journal of medicinal chemistry, 1989, Volume: 32, Issue:9

    Topics: Animals; Arachidonic Acids; Asthma; Benzoquinones; Bronchi; Bronchial Provocation Tests; Chemical Ph

1989
[Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:9

    Topics: Acetylcholine; Animals; Anti-Asthmatic Agents; Asthma; Benzoquinones; Guanidines; Guinea Pigs; Hepta

2004
Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 269, Issue:3

    Topics: Acetylcholine; Airway Resistance; Animals; Antibodies; Asthma; Benzoquinones; Bronchoalveolar Lavage

1994
Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414.
    Biological & pharmaceutical bulletin, 1994, Volume: 17, Issue:3

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Asthma; Benzoquinones;

1994
[Study on the inhibitory effect of AA-2414 on platelet aggregation and its clinical effect in asthmatic patients].
    Arerugi = [Allergy], 1993, Volume: 42, Issue:1

    Topics: Adult; Aged; Asthma; Benzoquinones; Female; Heptanoic Acids; Humans; In Vitro Techniques; Male; Midd

1993
Effects of Y-24180, a long-acting and potent antagonist to platelet-activating factor, on immediate asthmatic response in guinea pigs.
    Pharmacology, 1997, Volume: 54, Issue:1

    Topics: Animals; Anti-Asthmatic Agents; Asthma; Azepines; Benzoquinones; Bronchodilator Agents; Chromones; D

1997
Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1997, Volume: 46, Issue:4

    Topics: Administration, Oral; Aerosols; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Azepin

1997
Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics.
    Prostaglandins, leukotrienes, and essential fatty acids, 1998, Volume: 59, Issue:3

    Topics: Anti-Asthmatic Agents; Asthma; Benzoquinones; Bronchial Hyperreactivity; Eosinophils; Female; Forced

1998
In vitro responses to antigen stimulation: comparison between human lung parenchyma resected from asthmatic patients and non-asthmatic patients.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:2

    Topics: Aged; Airway Resistance; Animals; Antigens; Ascaris; Asthma; Benzoquinones; Dinoprost; Dogs; Female;

1999
Repeated antigen inhalations alter chemical mediators that cause asthmatic obstruction in guinea pigs.
    Japanese journal of pharmacology, 1999, Volume: 81, Issue:1

    Topics: Administration, Inhalation; Airway Obstruction; Aluminum Hydroxide; Animals; Antigens; Asthma; Benzo

1999
Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs.
    Japanese journal of pharmacology, 2000, Volume: 82, Issue:4

    Topics: Acetylcholine; Airway Resistance; Animals; Anti-Asthmatic Agents; Antigens; Asthma; Benzoquinones; B

2000
Effect of combined leukotriene D(4) and thromboxane A(2) receptor antagonist on mediator-controlled resistance in guinea pigs.
    European journal of pharmacology, 2000, Sep-01, Volume: 403, Issue:1-2

    Topics: Administration, Oral; Airway Resistance; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, N

2000
[Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients].
    Arerugi = [Allergy], 2001, Volume: 50, Issue:6

    Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Female; Heptanoic Acids; Humans; Male; Mi

2001
Effect of the prostaglandin endoperoxide antagonist AA-2414 on experimental allergic asthma.
    Annals of the New York Academy of Sciences, 1991, Volume: 629

    Topics: Animals; Asthma; Benzoquinones; Bronchoconstriction; Guinea Pigs; Heptanoic Acids; Immunoglobulin G;

1991
[Clinical study on the inhibitory effect of AA-2414 on platelet function in asthmatic patients].
    Arerugi = [Allergy], 1990, Volume: 39, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Benzoquinones; Heptanoic Acids; Humans; Middl

1990
A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids.
    Prostaglandins, 1989, Volume: 38, Issue:1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Admi

1989